Immune globulin (human) - Biologic Drug Details

✉ Email this page to a colleague

Summary for immune globulin (human)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for immune globulin (human)

Recent Clinical Trials for immune globulin (human)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Washington University School of Medicine	PHASE1
University of Utah	PHASE1
National Heart, Lung, and Blood Institute (NHLBI)	PHASE1

See all immune globulin (human) clinical trials

Pharmacology for immune globulin (human)

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for immune globulin (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for immune globulin (human) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for immune globulin (human) Derived from Patent Text Search

No patents found based on company disclosures

Immune Globulin (Human): Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What drives demand for immune globulin (human) biologics?

Immune globulin (human) products are used to prevent or treat antibody deficiencies and immune-mediated diseases. The demand base clusters around three clinical drivers:

Primary immunodeficiency (PID) replacement therapy: Lifelong or long-duration IVIG (intravenous) or SCIG (subcutaneous) treatment sustains steady consumption.
Immune-mediated and inflammatory indications: Autoimmune neuropathies (eg, CIDP), immune thrombocytopenia (ITP), and other off-label and label-driven uses expand patient populations and dosing frequency.
Hospital and payer reimbursement patterns: IVIG is typically hospital or infusion-center administered; SCIG shifts care to home or office administration, often aligning with payer incentives tied to reduced infusion-resource use.

System-level demand variables

Patient prevalence and adherence: PID patient counts grow with diagnosis rates and improved survival.
Administration modality: SCIG has gained share as providers and payers manage capacity and patient quality-of-life.
Supply constraints: IVIG is derived from human plasma. Collection variability and plasma availability can move pricing and short-term volumes.
Regulatory scrutiny: Label updates and safety communications shape channel inventory planning and clinician uptake.

How does competition shape pricing and share?

Competition is less about “same molecule” substitution and more about:

Route and brand (IVIG vs SCIG)
Product differentiation (formulation, dosing regimen, tolerability profile, and manufacturing platform)
Access and contracting (tendering, group purchasing organization terms, and national payer formularies)

Typical competitive dynamics

SCIG is a share-shift lever. When payers favor home-based treatment and providers can support nurse training and monitoring, SCIG products often win formulary access.
IVIG pricing is more volatile. Demand spikes, plasma collection cycles, and infusion capacity affect acquisition costs and contracted pricing rollovers.
Portfolio depth matters. Companies with both IVIG and SCIG options can defend share across routes during payer transitions.

What are the market impacts of plasma sourcing and supply risk?

Immune globulin (human) demand is relatively stable, but supply is not perfectly elastic because plasma is a finite input. When plasma collection tightens:

Wholesale acquisition costs and contract prices tend to rise.
Hospitals and infusion networks adjust ordering patterns, which can temporarily create “lumpiness” in reported sales.
Manufacturers prioritize higher-margin contracts or existing treaty terms, affecting regional mix.

When plasma supply loosens:

Pricing pressure increases and rebate intensity can rise.
Customers move toward just-in-time ordering, lowering inventory-carrying costs but increasing quarterly variability.

What regulatory and safety dynamics affect commercial trajectory?

Immune globulin products have long-standing safety protocols (infusion reactions, thromboembolic risk considerations, and renal risk mitigation practices). Commercial trajectory is influenced by:

Risk-management requirements in label language and REMS-like operational expectations.
Safety communications that cause physicians to revise infusion rates, patient selection, and concomitant prophylaxis.

Even without major label changes, safety communications can influence utilization patterns through institutional policy updates and prior authorization behavior.

Financial trajectory: how revenue typically moves for immune globulin (human)

The financial path for immune globulin (human) products is usually shaped by a combination of:

Volume growth from indication expansion and diagnosis
Price and mix from contract renewals
Channel inventory cycles
Switching between IVIG and SCIG
Manufacturing and supply events

A standard trajectory pattern in this therapeutic class is:

Steady baseline from PID replacement therapy.
Discrete step-ups when new indications receive approval or when payer coverage broadens.
Temporary revenue variability driven by plasma input changes and distribution lead times.

What do investors and operators watch in quarterly reporting?

Immune globulin (human) performance typically needs to be interpreted through these metrics:

Net sales growth vs. prior period
- Separate underlying volume movement from price and contracting effects.
Mix shift (IVIG to SCIG)
- Route switching can alter ASP dynamics and payer contracting structures.
Patient growth and persistence
- For PID, persistence tends to be high; for immune-mediated indications, adoption can be more variable.
Geographic mix
- Formularies and tender regimes create regional revenue differences.
Inventory and returns
- Channel stocking or destocking can distort near-term revenue.

Market sizing and growth: where expansion comes from

For immune globulin (human), growth tends to come from four sources:

More diagnosed patients in PID and related immune disorders.
Broader guideline uptake for immune-mediated diseases.
SCIG migration driven by care setting changes.
Portfolio expansion through lifecycle management (new formulations, dosing convenience, and administration improvements).

Competitive and product-family dynamics: the route and regimen effect

Immune globulin (human) commercial outcomes are often determined by the regimen that best aligns with payer and clinical workflow:

IVIG: Higher institutional concentration; tends to be linked to infusion capacity and inpatient/outpatient scheduling.
SCIG: Home-based administration; can increase persistence and reduce infusion-center reliance, which can be attractive to payers managing fixed infusion infrastructure.

This creates a “route competition” dynamic: companies with both IVIG and SCIG products can retain patients if clinicians and payers shift modalities over time.

Key business risks that can break the financial trajectory

For immune globulin (human), the largest downside risks are typically:

Plasma supply constraints leading to allocation and lost sales.
Adverse safety events that change institutional infusion protocols.
Payer formulary restrictions or contracting changes that reduce net pricing.
Higher-than-expected manufacturing costs tied to process changes or regulatory requirements.
Competitive displacement when SCIG adoption accelerates faster than expected or when switching incentives favor rivals.

Key Takeaways

Immune globulin (human) demand is anchored by PID replacement therapy and supported by immune-mediated indications, but quarterly performance is strongly influenced by route mix (IVIG vs SCIG) and plasma-driven supply conditions.
Pricing and share are primarily determined by contracting and access rather than pure therapeutic class competition, with SCIG migration a central lever for sustained share gains.
Financial trajectory typically shows stable baseline revenue plus step-ups from label/guideline-driven uptake, offset by inventory and supply cycle variability.
The dominant risks are plasma availability, safety-driven utilization shifts, and payer contracting moves that compress net price.

FAQs

1) What is the main structural demand driver for immune globulin (human)?

Primary immunodeficiency replacement therapy, which creates long-duration treatment persistence and supports stable baseline demand.

2) Does IVIG or SCIG usually grow faster in commercial mix?

SCIG often grows faster where payers and providers support home-based administration and operational workflows that improve persistence and reduce infusion-center dependency.

3) What most often causes quarter-to-quarter volatility?

Channel inventory movements and allocation-related supply timing driven by plasma collection cycles and distribution lead times.

4) How do payers typically influence outcomes?

Through formulary access, prior authorization requirements, and contracting terms that determine net pricing and preferred route selection.

5) What are the highest-impact downside risks for revenue?

Plasma supply constraints that limit allocations, and payer or safety-driven changes that reduce utilization or force protocol changes.

References

[1] U.S. Food and Drug Administration. “Drug Label Information for Immune Globulin (Human).” FDA Drug Labels database. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] World Health Organization (WHO). “Guidelines on the Use of Immunoglobulin in Clinical Practice.” WHO publications and immunoglobulin guidance resources. https://www.who.int/
[3] European Medicines Agency (EMA). “EPARs and Product Information for Human Immunoglobulin Products.” EMA medicine database. https://www.ema.europa.eu/

More… ↓

⤷ Start Trial